Prostin F2 Alpha (dinoprost trometamol): discontinuation of supply of medicine
Health professionals are advised that Prostin F2 Alpha (dinoprost trometamol) was discontinued from the Australian market by the sponsor, Pfizer, on 31 March 2015.
Alternative products available
Alternatives are available under the Special Access Scheme. To access alternatives please contact your hospital pharmacy.
The TGA published details of the discontinuation on the TGA Medicines Shortages website on 30 September 2014. Since this time the TGA has been working with sponsors and professional bodies to ensure health professionals are informed about the discontinuance. We have also been working to identify alternative products.
Prostin F2 Alpha (dinoprost trometamol) is used in evacuating the uterus in cases of foetal death and the therapeutic termination of pregnancy and it is also used for the non-surgical treatment for the evacuation of hydatidiform moles. Prostaglandin F2 Alpha (dinoprost trometamol) is also used in obstetric facilities for the treatment of severe postpartum haemorrhage. Clinicians are referred to The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) College Statements and Guidelines for the Management of Postpartum Haemorrhage. Prostaglandin F2 Alpha (dinoprost trometamol) is only used in hospitals or locations with facilities for emergency obstetric and gynaecological care.
Consumers and health professionals are encouraged to report problems with medicines or vaccines. Your report will contribute to the TGA's monitoring of these products.
The TGA cannot give advice about an individual's medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse events associated with a medicine, vaccine or medical device.